Tenapanor administration and the activity of the H(+)‐coupled transporter PepT1 in healthy volunteers

AIM: Tenapanor (RDX5791/AZD1722), an inhibitor of gastrointestinal Na(+)/H(+) exchanger NHE3, is being evaluated for the treatment of patients with constipation‐predominant irritable bowel syndrome and the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis. By reduci...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Susanne, Rosenbaum, David P., Palm, Johan, Stefansson, Bergur, Knutsson, Mikael, Lisbon, Eleanor A., Hilgendorf, Constanze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582369/
https://www.ncbi.nlm.nih.gov/pubmed/28432691
http://dx.doi.org/10.1111/bcp.13313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582369/
https://www.ncbi.nlm.nih.gov/pubmed/28432691
http://dx.doi.org/10.1111/bcp.13313

Ejemplares similares